Levaquin Damages Reduced on Appeal

Johnson & Johnson has won a partial court victory in its long-running battle over the antibiotic Levaquin. The drugmaker has faced thousands of lawsuits claiming Levaquin caused tendon injuries–and that J&J didn’t do enough to warn patients and doctors of the risk.

Just last month, J&J settled at least 845 of the more than 3,400 Levaquin cases, and at last count it was negotiating to settle 190 more. Four of the Levaquin lawsuits have gone to trial, and J&J won three. In the fourth–in which the plaintiff, John Schedin, claimed Levaquin caused both of his Achilles tendons to rupture–a jury awarded more than $2 million in damages.

Now, however, the U.S. Court of Appeals in St. Louis has tossed out $1.1 million in punitive damages, leaving $630,000 in compensation for Schedin’s injuries. The appeals court upheld the jury’s determination that J&J didn’t properly warn about Levaquin’s tendon injury risk.

A three-judge panel for the U.S. Court of Appeals for the Eight Circuit ruled, in a split decision, that there was not enough evidence to show that Johnson & Johnson deliberately hid or downplayed data linking the popular antibiotic to an increased risk of tendon damage.

“The evidence is neither clear nor convincing, as a matter of law, that OMJP deliberately disregarded the safety of the users of Levaquin,” U.S. Circuit Judge William Jay Riley said today. Proving deliberate disregard is “required for punitive damages under Minnesota law,” Riley said.

Judge Kermit Bye disagreed with the other two judges on the panel, indicating that there was enough evidence for the jury to conclude that Ortho-McNeil-Janssen purposefully deceived the public.

“I believe…there was sufficient evidence from which a reasonable jury could conclude OMJP deliberately disregarded the risk of tendon injuries in elderly patients who were prescribed Levaquin in association with corticosteroids,” Judge Bye wrote in the dissenting opinion. “I therefore respectfully dissent from the decision to reverse the denial of OMJP’s motion for judgment as a matter of law on punitive damages.”

Schedin, 84, who said he ruptured both Achilles tendons after taking Levaquin, claimed the companies failed to warn doctors and patients of the drug’s association with tendon damage.

Levaquin’s official label includes a “black box” warning of the risk of tendon ruptures–a warning the FDA added in 2008 on all antibiotics in Levaquin’s class. Lawyers have argued that Levaquin was risker than the others in that class, but J&J points out that Levaquin’s label covered the potential for tendon-related side effects as far back as 1996.



, , , , , ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.